Harmony Biosciences Holdings (HRMY) Payables (2019 - 2026)

Harmony Biosciences Holdings has disclosed Payables across 8 years of filings, most recently posting $28.6 million for Q1 2026.

• Payables for Q1 2026 came in at $28.6 million, up 63.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (up 63.81% YoY), and the FY2025 annual result was $17.7 million, up 28.73% from the prior year.
• Payables came in at $28.6 million for Q1 2026 at Harmony Biosciences Holdings, up from $17.7 million in the prior quarter.
• In the past five years, Payables ranged from a high of $28.6 million in Q1 2026 to a low of $3.8 million in Q4 2022.
• The 5-year median for Payables is $13.7 million (2024), against an average of $14.4 million.
• Peak annual rise in Payables reached 368.3% in 2023, while the deepest fall reached 34.93% in 2023.
• Harmony Biosciences Holdings' Payables stood at $3.8 million in 2022, then surged by 368.3% to $17.7 million in 2023, then declined by 22.48% to $13.7 million in 2024, then rose by 28.73% to $17.7 million in 2025, then soared by 61.65% to $28.6 million in 2026.
• The last three Payables figures came in at $28.6 million (Q1 2026), $17.7 million (Q4 2025), and $26.3 million (Q3 2025), per Business Quant data.